Supporting our data, HER2 IHC 3+ tumors showed more frequently yT0 and yN0, lower LNR, prognostic stage, ki67 expression and RTC after NACT, suggesting that the amount of HER2 protein overexpression on the cell surface regulates the efficacy of neoadjuvant therapy in HER2+ BC patients. Here, ERBB2 is linked to breast cancer.